Symbols / RYTM Stock $84.71 +0.43% Rhythm Pharmaceuticals, Inc.

Healthcare • Biotechnology • United States • NGM
RYTM (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Dr. David P. Meeker M.D.
Exch · Country NGM · United States
Market Cap 5.81B
Enterprise Value 5.69B
Income -207.84M
Sales 217.16M
FCF (ttm) -150.68M
Book/sh 2.07
Cash/sh 4.97
Employees 414
Insider 10d —
IPO Oct 09, 2017
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -106.64
PEG —
P/S 26.76
P/B 40.94
P/C —
EV/EBITDA -29.02
EV/Sales 26.21
Quick Ratio 3.63
Current Ratio 4.17
Debt/Eq 47.26
LT Debt/Eq —
EPS (ttm) -3.13
EPS next Y -0.79
EPS Growth —
Revenue Growth 83.80%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-08-04
Earnings (prior) 2026-05-05
ROA -29.76%
ROE -101.16%
ROIC —
Gross Margin 89.41%
Oper. Margin -87.11%
Profit Margin -93.33%
Shs Outstand 68.59M
Shs Float 55.70M
Insider Own 0.77%
Instit Own 110.02%
Short Float 12.18%
Short Ratio 10.71
Short Interest 8.28M
52W High 122.20
vs 52W High -30.68%
52W Low 60.70
vs 52W Low 39.56%
Beta 1.94
Impl. Vol. 97.78%
Rel Volume 0.50
Avg Volume 812.15K
Volume 408.89K
Target (mean) $138.20
Tgt Median $142.00
Tgt Low $105.00
Tgt High $159.00
# Analysts 15
Recom Strong_buy
Prev Close $84.35
Price $84.71
Change 0.43%
About

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases in the United States and internationally. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, Bardet-Biedl and Alström syndrome, Prader-Willi syndrome, and hypothalamic obesity. It is in Phase 3 clinical trials for treating acquired hypothalamic obesity, congenital hypothalamic obesity, pro-opiomelanocortin (POMC) and LEPR insufficiency obesities, SRC1 deficiency obesity, and SH2B1 deficiency obesity; and in phase 2 clinical trails for the treatment of Prader-Willi syndrome and MC4R deficiency. The company is also developing bivamelagon, an investigational oral small molecule MC4R agonist that is in phase 2 clinical trial for the treatment of MC4R pathway diseases; and RM-718, a next generation MC4R peptide agonist that is in phase 1 clinical trial for the treatment of hypothalamic obesity. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$138.20
Mean price target
2. Current target
$84.71
Latest analyst target
3. DCF / Fair value
$-39.54
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$84.71
Low
$105.00
High
$159.00
Mean
$138.20

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-05-07 main Canaccord Genuity Buy → Buy $143
2026-05-06 main RBC Capital Outperform → Outperform $137
2026-05-06 main Wells Fargo Overweight → Overweight $144
2026-03-23 main HC Wainwright & Co. Buy → Buy $105
2026-03-20 main Citigroup Buy → Buy $142
2026-03-20 main B of A Securities Buy → Buy $149
2026-03-20 main Citizens Market Outperform → Market Outperform $155
2026-03-18 main HC Wainwright & Co. Buy → Buy $100
2026-03-17 main Citigroup Buy → Buy $131
2026-03-17 main RBC Capital Outperform → Outperform $130
2026-03-17 main Citizens Market Outperform → Market Outperform $152
2026-03-17 main B of A Securities Buy → Buy $139
2026-03-17 main Morgan Stanley Overweight → Overweight $136
2026-03-17 main Needham Buy → Buy $130
2026-03-12 main Wells Fargo Overweight → Overweight $143
2026-03-02 main Canaccord Genuity Buy → Buy $140
2026-03-02 main HC Wainwright & Co. Buy → Buy $110
2026-02-27 main Wells Fargo Overweight → Overweight $136
2026-02-27 main Citizens Market Outperform → Market Outperform $176
2026-02-27 main Guggenheim Buy → Buy $143
News
RSS: Latest RYTM news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-05-18 SMITH HUNTER C Chief Financial Officer — 3,000 $17.87 $53,610
2026-05-15 GERMAN CHRISTOPHER PAUL Officer — 4,442 $17.97 $187,313
2026-05-15 GERMAN CHRISTOPHER PAUL Officer — 4,643 $92.21 $428,131
2026-04-01 MAZABRAUD YANN Officer — 12,875 — —
2026-03-04 GERMAN CHRISTOPHER PAUL Officer — 1,500 $17.97 $26,955
2026-03-04 GERMAN CHRISTOPHER PAUL Officer — 5,614 $89.56 $502,790
2026-03-02 SMITH HUNTER C Chief Financial Officer — 6,099 $6.80 $41,473
2026-02-27 GERMAN CHRISTOPHER PAUL Officer — 1,162 — —
2026-02-13 MAZABRAUD YANN Officer — 10,000 — —
2026-02-12 SMITH HUNTER C Chief Financial Officer — 7,071 $96.26 $708,576
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
189.76
+45.83%
130.13
+68.06%
77.43
+227.56%
23.64
Operating Revenue
189.76
+45.83%
130.13
+68.06%
77.43
+227.56%
23.64
Cost Of Revenue
19.49
+45.81%
13.37
+43.71%
9.30
+336.10%
2.13
Reconciled Cost Of Revenue
19.49
+45.81%
13.37
+43.71%
9.30
+336.10%
2.13
Gross Profit
170.26
+45.83%
116.76
+71.39%
68.13
+216.79%
21.50
Operating Expense
362.28
-5.23%
382.26
+51.40%
252.48
+25.83%
200.66
Research And Development
167.34
-29.68%
237.96
+76.33%
134.95
+24.23%
108.63
Selling General And Administration
194.94
+35.09%
144.30
+22.78%
117.53
+27.71%
92.03
Total Expenses
381.77
-3.50%
395.63
+51.13%
261.79
+29.09%
202.79
Operating Income
-192.02
+27.68%
-265.50
-44.02%
-184.36
-2.90%
-179.16
Total Operating Income As Reported
-192.02
+27.68%
-265.50
-44.02%
-184.36
-2.90%
-179.16
EBITDA
-174.12
+26.87%
-238.09
-41.33%
-168.46
+3.32%
-174.25
Normalized EBITDA
-174.12
+29.50%
-246.99
-46.61%
-168.46
+3.32%
-174.25
Reconciled Depreciation
1.34
-14.40%
1.56
-11.09%
1.76
+5.14%
1.67
EBIT
-175.46
+26.79%
-239.65
-40.79%
-170.22
+3.24%
-175.92
Total Unusual Items
—
8.90
—
—
Total Unusual Items Excluding Goodwill
—
8.90
—
—
Net Income
-196.54
+24.58%
-260.60
-41.11%
-184.68
-1.97%
-181.12
Pretax Income
-196.04
+24.67%
-260.26
-41.36%
-184.11
-1.65%
-181.12
Net Non Operating Interest Income Expense
-5.29
+10.22%
-5.89
-11216.98%
0.05
+104.52%
-1.17
Interest Expense Non Operating
20.58
-0.10%
20.60
+48.31%
13.89
+167.10%
5.20
Net Interest Income
-5.29
+10.22%
-5.89
-11216.98%
0.05
+104.52%
-1.17
Interest Expense
20.58
-0.10%
20.60
+48.31%
13.89
+167.10%
5.20
Interest Income Non Operating
15.29
+3.96%
14.71
+5.49%
13.95
+246.12%
4.03
Interest Income
15.29
+3.96%
14.71
+5.49%
13.95
+246.12%
4.03
Other Income Expense
1.26
-88.65%
11.14
+5762.63%
0.19
+124.05%
-0.79
Other Non Operating Income Expenses
1.26
-43.55%
2.24
+1078.42%
0.19
+124.05%
-0.79
Gain On Sale Of Security
—
8.90
—
—
Tax Provision
0.50
+43.64%
0.35
-38.65%
0.56
0.00
Tax Rate For Calcs
0.00
+0.00%
0.00
+0.00%
0.00
0.00
Tax Effect Of Unusual Items
0.00
-100.00%
1.87
0.00
0.00
Net Income Including Noncontrolling Interests
-196.54
+24.58%
-260.60
-41.11%
-184.68
-1.97%
-181.12
Net Income From Continuing Operation Net Minority Interest
-196.54
+24.58%
-260.60
-41.11%
-184.68
-1.97%
-181.12
Net Income From Continuing And Discontinued Operation
-196.54
+24.58%
-260.60
-41.11%
-184.68
-1.97%
-181.12
Net Income Continuous Operations
-196.54
+24.58%
-260.60
-41.11%
-184.68
-1.97%
-181.12
Normalized Income
-196.54
+26.56%
-267.63
-44.92%
-184.68
-1.97%
-181.12
Net Income Common Stockholders
-201.92
+23.68%
-264.57
-43.26%
-184.68
-1.97%
-181.12
Diluted EPS
-3.11
+28.34%
-4.34
-35.62%
-3.20
+7.78%
-3.47
Basic EPS
-3.11
+28.34%
-4.34
-35.62%
-3.20
+7.78%
-3.47
Basic Average Shares
64.98
+6.54%
61.00
+5.76%
57.67
+10.65%
52.12
Diluted Average Shares
64.98
+6.54%
61.00
+5.76%
57.67
+10.65%
52.12
Diluted NI Availto Com Stockholders
-201.92
+23.68%
-264.57
-43.26%
-184.68
-1.97%
-181.12
Preferred Stock Dividends
5.38
+35.47%
3.97
—
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
480.20
+22.41%
392.27
+17.89%
332.75
-13.00%
382.48
Current Assets
466.92
+24.78%
374.20
+21.39%
308.27
-12.98%
354.24
Cash Cash Equivalents And Short Term Investments
388.95
+21.33%
320.56
+16.21%
275.85
-17.23%
333.29
Cash And Cash Equivalents
54.30
-39.08%
89.14
+48.36%
60.08
-52.94%
127.68
Other Short Term Investments
334.65
+44.60%
231.43
+7.26%
215.76
+4.94%
205.61
Receivables
26.08
+40.89%
18.51
+24.52%
14.87
+138.87%
6.22
Accounts Receivable
26.08
+40.89%
18.51
+24.52%
14.87
+138.87%
6.22
Inventory
25.75
+37.42%
18.74
+117.31%
8.62
+195.65%
2.92
Raw Materials
6.75
-0.46%
6.78
+46.51%
4.62
+69.91%
2.72
Work In Process
1.63
+30.48%
1.25
+13.22%
1.10
0.00
Finished Goods
17.38
+62.17%
10.71
+270.12%
2.90
+1384.62%
0.20
Prepaid Assets
16.17
+113.27%
7.58
+235.55%
2.26
-48.57%
4.39
Other Current Assets
9.97
+13.24%
8.80
+31.92%
6.67
-10.02%
7.42
Total Non Current Assets
13.28
-26.52%
18.07
-26.16%
24.48
-13.34%
28.25
Net PPE
4.15
+1.07%
4.11
+93.64%
2.12
-37.20%
3.38
Gross PPE
9.40
+5.93%
8.88
+43.60%
6.18
-5.40%
6.53
Accumulated Depreciation
-5.25
-10.11%
-4.77
-17.44%
-4.06
-28.65%
-3.15
Properties
0.00
0.00
0.00
0.00
Machinery Furniture Equipment
2.69
+0.00%
2.69
-0.04%
2.69
+1.81%
2.65
Construction In Progress
0.93
0.00
—
—
Other Properties
3.05
-12.31%
3.48
+345.20%
0.78
-33.93%
1.18
Leases
2.73
+1.04%
2.71
+0.00%
2.71
+0.00%
2.71
Goodwill And Other Intangible Assets
5.32
-13.85%
6.17
-12.15%
7.03
-10.85%
7.88
Other Non Current Assets
3.81
-51.12%
7.79
-49.17%
15.33
-9.75%
16.98
Total Liabilities Net Minority Interest
210.17
-7.71%
227.72
+39.72%
162.99
+37.87%
118.22
Current Liabilities
105.94
-8.29%
115.52
+109.26%
55.20
+38.67%
39.81
Payables And Accrued Expenses
93.72
+32.69%
70.64
+47.97%
47.74
+35.34%
35.27
Payables
13.95
+13.13%
12.33
+152.36%
4.88
+1.83%
4.80
Accounts Payable
13.95
+13.13%
12.33
+152.36%
4.88
+1.83%
4.80
Current Accrued Expenses
79.78
+36.82%
58.31
+36.07%
42.85
+40.61%
30.48
Current Debt And Capital Lease Obligation
0.65
—
0.77
+12.57%
0.68
Current Capital Lease Obligation
0.65
0.00
-100.00%
0.77
+12.57%
0.68
Current Deferred Liabilities
7.49
+164.95%
2.83
+119.83%
1.29
-10.32%
1.43
Current Deferred Revenue
0.19
-84.91%
1.29
+0.00%
1.29
-10.32%
1.43
Other Current Liabilities
4.08
-90.31%
42.05
+677.34%
5.41
+123.65%
2.42
Total Non Current Liabilities Net Minority Interest
104.23
-7.11%
112.21
+4.10%
107.78
+37.46%
78.41
Long Term Debt And Capital Lease Obligation
3.34
-15.13%
3.94
+703.67%
0.49
-61.11%
1.26
Long Term Capital Lease Obligation
3.34
-15.13%
3.94
+703.67%
0.49
-61.11%
1.26
Non Current Deferred Liabilities
100.89
-6.82%
108.27
+2.00%
106.14
+40.01%
75.81
Stockholders Equity
270.03
+64.10%
164.55
-3.07%
169.76
-35.76%
264.26
Common Stock Equity
139.07
+540.02%
21.73
-87.20%
169.76
-35.76%
264.26
Capital Stock
131.02
-8.30%
142.88
+242071.19%
0.06
+5.36%
0.06
Common Stock
0.07
+9.84%
0.06
+3.39%
0.06
+5.36%
0.06
Preferred Stock
130.96
-8.31%
142.82
0.00
0.00
Share Issued
67.21
+7.72%
62.39
+4.99%
59.43
+4.97%
56.61
Ordinary Shares Number
67.21
+7.72%
62.39
+4.99%
59.43
+4.97%
56.61
Additional Paid In Capital
1,491.67
+26.73%
1,177.05
+10.59%
1,064.30
+9.23%
974.36
Retained Earnings
-1,351.88
-17.01%
-1,155.34
-29.13%
-894.74
-26.01%
-710.06
Gains Losses Not Affecting Retained Earnings
-0.80
-1941.03%
-0.04
-129.10%
0.13
+245.65%
-0.09
Other Equity Adjustments
-0.80
-1941.03%
-0.04
-129.10%
0.13
+245.65%
-0.09
Total Equity Gross Minority Interest
270.03
+64.10%
164.55
-3.07%
169.76
-35.76%
264.26
Total Capitalization
270.03
+64.10%
164.55
-3.07%
169.76
-35.76%
264.26
Working Capital
360.97
+39.54%
258.68
+2.22%
253.06
-19.52%
314.43
Invested Capital
139.07
+540.02%
21.73
-87.20%
169.76
-35.76%
264.26
Total Debt
3.99
+1.37%
3.94
+212.54%
1.26
-35.19%
1.94
Capital Lease Obligations
3.99
+1.37%
3.94
+212.54%
1.26
-35.19%
1.94
Net Tangible Assets
264.71
+67.14%
158.38
-2.68%
162.73
-36.53%
256.38
Tangible Book Value
133.75
+759.85%
15.55
-90.44%
162.73
-36.53%
256.38
Derivative Product Liabilities
0.00
0.00
-100.00%
1.15
-14.18%
1.34
Preferred Stock Equity
130.96
-8.31%
142.82
—
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-115.67
-1.58%
-113.88
+16.36%
-136.16
+21.49%
-173.43
Cash Flow From Continuing Operating Activities
-115.67
-1.58%
-113.88
+16.36%
-136.16
+21.49%
-173.43
Net Income From Continuing Operations
-196.54
+24.58%
-260.60
-41.11%
-184.68
-1.97%
-181.12
Depreciation Amortization Depletion
1.34
-14.40%
1.56
-11.09%
1.76
+5.14%
1.67
Depreciation And Amortization
1.34
-14.40%
1.56
-11.09%
1.76
+5.14%
1.67
Other Non Cash Items
21.10
-81.39%
113.39
+483.63%
19.43
+279.30%
5.12
Stock Based Compensation
66.82
+68.38%
39.68
+21.90%
32.55
+64.15%
19.83
Operating Gains Losses
-0.91
+91.18%
-10.32
-5331.58%
-0.19
-124.05%
0.79
Gain Loss On Investment Securities
-0.91
+91.18%
-10.32
-5331.58%
-0.19
-124.05%
0.79
Change In Working Capital
-0.97
-109.15%
10.57
+119.99%
4.81
+127.61%
-17.41
Change In Receivables
-7.57
-107.68%
-3.65
+57.83%
-8.64
-66.24%
-5.20
Changes In Account Receivables
-7.57
-107.68%
-3.65
+57.83%
-8.64
-66.24%
-5.20
Change In Inventory
-7.47
+26.12%
-10.12
-77.27%
-5.71
-103.39%
-2.81
Change In Prepaid Assets
-6.33
-14.54%
-5.52
-292.07%
2.88
+477.51%
0.50
Change In Payables And Accrued Expense
21.89
-0.12%
21.92
+48.37%
14.77
+857.42%
1.54
Change In Payable
21.89
-0.12%
21.92
+48.37%
14.77
+857.42%
1.54
Change In Account Payable
21.89
-0.12%
21.92
+48.37%
14.77
+857.42%
1.54
Change In Other Working Capital
-1.09
—
-0.15
+97.76%
-6.61
Change In Other Current Assets
-0.40
-105.00%
7.94
+379.65%
1.66
+134.21%
-4.84
Investing Cash Flow
-137.15
-184.71%
-48.17
-750.36%
-5.67
-120.21%
28.03
Cash Flow From Continuing Investing Activities
-137.15
-184.71%
-48.17
-750.36%
-5.67
-120.21%
28.03
Net PPE Purchase And Sale
-0.95
0.00
+100.00%
-0.05
+83.27%
-0.28
Purchase Of PPE
-0.95
0.00
+100.00%
-0.05
+83.27%
-0.28
Capital Expenditure
-0.95
—
-0.05
+98.90%
-4.28
Net Investment Purchase And Sale
-96.20
-1153.75%
-7.67
-15759.18%
0.05
-99.85%
32.31
Purchase Of Investment
-348.67
-29.95%
-268.31
+24.40%
-354.92
-40.88%
-251.94
Sale Of Investment
252.47
-3.13%
260.64
-26.57%
354.97
+24.88%
284.25
Net Business Purchase And Sale
—
—
0.00
0.00
Gain Loss On Sale Of Business
—
—
0.00
0.00
Net Intangibles Purchase And Sale
—
0.00
0.00
+100.00%
-4.00
Purchase Of Intangibles
—
0.00
0.00
+100.00%
-4.00
Net Other Investing Changes
-40.00
+1.23%
-40.50
-614.66%
-5.67
—
Financing Cash Flow
217.96
+13.97%
191.24
+157.16%
74.37
-65.22%
213.83
Cash Flow From Continuing Financing Activities
217.96
+13.97%
191.24
+157.16%
74.37
-65.22%
213.83
Net Common Stock Issuance
222.69
+468.88%
39.15
-19.91%
48.88
-62.72%
131.11
Proceeds From Stock Option Exercised
15.19
-11.93%
17.25
+102.39%
8.52
-17.89%
10.38
Net Other Financing Charges
-19.92
-397.93%
-4.00
-123.57%
16.97
-76.54%
72.34
Changes In Cash
-34.87
-219.44%
29.19
+143.27%
-67.45
-198.58%
68.43
Effect Of Exchange Rate Changes
0.09
+4250.00%
0.00
+101.41%
-0.14
0.00
Beginning Cash Position
89.60
+48.32%
60.41
-52.81%
128.00
+114.86%
59.58
End Cash Position
54.82
-38.81%
89.60
+48.32%
60.41
-52.81%
128.00
Free Cash Flow
-116.63
-2.41%
-113.88
+16.39%
-136.20
+23.36%
-177.71
Amortization Of Securities
-6.52
+20.20%
-8.16
+16.98%
-9.84
-325.02%
-2.31
Common Stock Issuance
222.69
+468.88%
39.15
-19.91%
48.88
-62.72%
131.11
Issuance Of Capital Stock
222.69
+25.11%
178.00
+264.19%
48.88
-62.72%
131.11
Net Preferred Stock Issuance
0.00
-100.00%
138.85
0.00
0.00
Preferred Stock Issuance
0.00
-100.00%
138.85
0.00
0.00
Sale Of Business
—
—
0.00
0.00
Sale Of Intangibles
—
—
0.00
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category